This proposal outlines a 5-year training plan designed to equip the applicant with tools that will foster her success as an academic investigator with a focus on hematopoiesis and myeloproliferative neoplasm (MPN) research. Applicant: She has completed rigorous clinical training in both internal medicine and hematology- oncology and has spent the past two years acquiring experience in both basic and clinical Hematology research in her prior mentors'laboratories. The proposed career development program has been designed to further develop the most novel aspects of her research and to promote her development into an independent physician-scientist. Mentors: The primary mentor, Dr. Christopher Cardozo, is a VA investigator and will provide day to day guidance about laboratory work and the career development of the applicant. Dr. Cardozo has 20 years experience in biochemistry and molecular biology and is internationally known for his contributions to our understanding of the molecular mechanism of androgen action on muscle stem cells, and recognized for his efforts in promoting research and development at the James J. Peters VA (JJPVA) Medical Center. The secondary mentor, Dr. Riccardo Dalla-Favera, is highly respected in the field of molecular genetics and internationally-recognized for his contribution to our understanding of oncogenes and microRNAs (miRNA) in hematologic malignancies. The secondary mentor Dr. Azra Raza is internationally known for landmark observations regarding the biology and treatment of MPNs. All three mentors are physician-scientists who have guided the successful development of many young investigators. The mentoring team will provide synergistic guidance about career development within the VA, laboratory methods, miRNA biology and MPN pathogenesis. The JJPVA Medical Center and its affiliate Columbia University Medical Center are deeply committed to the development of the applicant as an independent investigator. Research plan: The research plan follows naturally from the applicant's recent novel work generating a JAK2V617F-positive induced pluripotent stem (iPS) cell line from peripheral blood CD34+ cells from an MPN patient, and from a separate study which identified candidate miRNAs that may contribute to MPN stem cell pool expansion and hematopoietic lineage commitment. MiRNAs regulate hematopoiesis in both hematopoietic stem cells and committed progenitor cells. MPN is a stem cell disorder. However, there has been no miRNA expression analysis in MPN stem cells to date. Here, we propose to study the roles of these deregulated miRNAs in JAK2V617F-positive hematopoietic stem/progenitor cell expansion and hematopoietic lineage commitment. Both patient peripheral blood CD34+ cells and the JAk2V617F-positive iPS cell line will be used to study the candidate miRNAs'in vivo expression and in vitro function. The underlying mechanisms in hematopoietic cell signal transduction will also be explored. This training program will provide the applicant with valuable skills and will serve as the foundation for a successful career in translational hematology investigation. Relevance: MPNs represent an underserved group of disorders affecting veterans and non-veterans with significant disease- related morbidity and mortality. The only treatment currently available is supportive care. Significance: The proposed work will address this unique opportunity in the VA health care system and fill important gaps in our knowledge of miRNA deregulation in MPN stem cells which hold the potential to promote the development of novel diagnostic and therapeutic capabilities in MPN.
Chronic myeloproliferative neoplasms (MPNs) include three distinct disorders each of which affects patients at all ages. These disorders have diverse and overlapping clinical manifestations, which often confounds their diagnosis. Because of the lack of a specific diagnostic test, their diagnosis is often delayed, leading to significant disease-related complications. Deficits in our understanding of MPN also contribute to the lack of effective targeted therapy;currently, treatment options are limited to supportive care. Knowledge regarding the molecular and cellular processes to aid better diagnosis and therapy is thus highly relevant to public health.
|Lin, Chi Hua Sarah; Zhang, Yu; Kaushansky, Kenneth et al. (2018) JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury. Haematologica 103:1160-1168|
|Zhan, H; Lin, C H S; Segal, Y et al. (2018) The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Leukemia 32:462-469|
|Zhan, H; Ma, Y; Lin, C H S et al. (2016) JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. Leukemia 30:2332-2341|
|Lin, Chi Hua Sarah; Kaushansky, Kenneth; Zhan, Huichun (2016) JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms. Blood Cells Mol Dis 62:42-48|
|Zhan, Huichun; Ciano, Kristen; Dong, Katherine et al. (2015) Targeting glutamine metabolism in myeloproliferative neoplasms. Blood Cells Mol Dis 55:241-7|
|Zhan, Huichun; Cardozo, Christopher; Raza, Azra (2013) MicroRNAs in myeloproliferative neoplasms. Br J Haematol 161:471-83|
|Zhan, Huichun; Cardozo, Christopher; Yu, Wayne et al. (2013) MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis 50:190-5|